| Dr Vukman Soskic, MD | |
|
3600 Nw Samaritan Dr, Corvallis, OR 97330-3737 | |
| (541) 768-5111 | |
| Not Available |
| Full Name | Dr Vukman Soskic |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 34 Years |
| Location | 3600 Nw Samaritan Dr, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629269287 | NPI | - | NPPES |
| 006513 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD27729 (Oregon) | Secondary |
| 207R00000X | Internal Medicine | MD27729 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Regional Medical Center | Corvallis, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Good Samaritan Hospital Corvallis | 1557270725 | 339 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20031111000297 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
| Entity Name | Good Samaritan Hospital Corvallis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453134 PECOS PAC ID: 1557270725 Enrollment ID: O20031125000163 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20040120000329 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174888010 PECOS PAC ID: 2466353529 Enrollment ID: O20040204000304 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
| Entity Name | Albany General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154372340 PECOS PAC ID: 9931097987 Enrollment ID: O20040310000310 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20061104000117 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1801847066 PECOS PAC ID: 2466353529 Enrollment ID: O20061104000163 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vukman Soskic, MD Po Box 1189, Corvallis, OR 97339-1189 Ph: () - | Dr Vukman Soskic, MD 3600 Nw Samaritan Dr, Corvallis, OR 97330-3737 Ph: (541) 768-5111 |
News Archive
A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses - B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.
In the current uncertain economic climate, researchers say for those on the brink of retirement, money is more of an issue now than it was two years ago and many potential retirees have been forced to re-think their retirement plans.
Your microbiota may not be on your side as you try improving your diet this New Year's. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don't have an immediate response to their new program.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.
› Verified 3 days ago
Tomer Pelleg, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3600 Nw Samaritan Dr Ste 227, Corvallis, OR 97330 Phone: 541-768-1261 | |
Dr. Parinav Kanwar, Internal Medicine Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-4906 | |
Dr. Stanley J. Nudelman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3521 Nw Samaritan Dr, Suite 201, Corvallis, OR 97330 Phone: 541-768-5140 | |
Dr. Randall V. Bream, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3600 Nw Samaritan Dr, Suite E350, Corvallis, OR 97330 Phone: 541-768-5205 Fax: 541-768-5206 | |
Jonathan David Jones, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3620 Nw Samaritan Dr Ste 202, Corvallis, OR 97330 Phone: 541-768-5800 | |
Gemechu Abraham Geleto, Internal Medicine Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-4906 | |
Roland Solensky, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 |